Baker Bros. Advisors’s Alder Biopharmaceuticals ALDR Stock Holding History

Baker Bros. Advisors’s Portfolio ALDR Stock Details ALDR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-217,328	Closed	-$2.49M	–	127
2017 Q2	$2.49M	Hold	217,328	–	–	0.02%	79
2017 Q1	$4.52M	Hold	217,328	–	–	0.04%	66
2016 Q4	$4.52M	Hold	217,328	–	–	0.04%	68
2016 Q3	$7.12M	Hold	217,328	–	–	0.06%	61
2016 Q2	$5.43M	Buy	+217,328	New	+$5.88M	0.06%	68
2015 Q4	–	Sell	-513,439	Closed	-$16.8M	–	138
2015 Q3	$16.8M	Sell	513,439 -378,249	-42%	-$16.1M	0.16%	46
2015 Q2	$47.2M	Buy	891,688 +12,107	+1%	+$440K	0.41%	27
2015 Q1	$25.4M	Buy	879,581 +726,231	+474%	+$19.9M	0.21%	38
2014 Q4	$4.46M	Hold	153,350	–	–	0.05%	75
2014 Q3	$1.94M	Hold	153,350	–	–	0.02%	87
2014 Q2	$3.08M	Buy	+153,350	New	+$2.16M	0.04%	83

Other funds holding ALDR

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Baker Bros. Advisors's ALDR Position: Q3 2017 in Review

Baker Bros. Advisors sold out of Alder Biopharmaceuticals (ALDR) in Q3 2017, closing a stake of 217,328 shares — an estimated $2.49M sold.

Baker Bros. Advisors first reported a position in ALDR in Q2 2014 and held it in 11 quarters. The position peaked at $47.2M in Q2 2015. 132 funds tracked by Wall St. Rank hold ALDR as of Q3 2017.

Baker Bros. Advisors reported no remaining Alder Biopharmaceuticals position as of Q3 2017 after selling out during the quarter.
Baker Bros. Advisors sold 217,328 Alder Biopharmaceuticals shares in Q3 2017, an estimated $2.49M.
Baker Bros. Advisors first reported a position in Alder Biopharmaceuticals in Q2 2014 and held it in 11 quarters.
Baker Bros. Advisors's Alder Biopharmaceuticals position peaked at $47.2M in Q2 2015.
132 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q3 2017.

Based on Baker Bros. Advisors's 13F filing for Q3 2017, filed 14 Nov 2017.